Company Overview of Foresight Biotherapeutics, Inc.
Foresight Biotherapeutics, Inc. develops treatments and therapies to address unmet needs in ophthalmology and otolaryngology. Its products include FST-100 for the clinical needs of microbial eradication and reduction in inflammation associated with ocular infections, as well as for adenoviral conjunctivitis; and FST-201, a topical formulation of povidone-iodine and dexamethasone for the treatment of acute otitis media. The company was incorporated in 2008 and is based in New York, New York. As of July 30, 2015, Foresight Biotherapeutics, Inc. operates as a subsidiary of Shire plc.
50 West 57th Street
New York, NY 10019
Founded in 2008
Key Executives for Foresight Biotherapeutics, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Foresight Biotherapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.